Tumor Biology

, Volume 37, Issue 2, pp 2049–2055 | Cite as

Application of plasma circulating microRNA-448, 506, 4316, and 4478 analysis for non-invasive diagnosis of lung cancer

  • Tomasz Powrózek
  • Paweł Krawczyk
  • Dariusz M. Kowalski
  • Barbara Kuźnar-Kamińska
  • Kinga Winiarczyk
  • Marta Olszyna-Serementa
  • Halina Batura-Gabryel
  • Janusz Milanowski
Original Article


Aberrant expression of microRNAs (miRNAs) in cancer patients compared to healthy people as well as possibility of detection of these molecules in blood samples make them potential biomarkers of various cancers. In the present study, we investigated the potential role of four miRNAs as lung cancer (LC) biomarkers: miRNA-448, 506, 4316, and 4478. Using quantitative reverse transcription polymerase chain reaction (qRT-PCR) technique, we assessed expression of studied miRNAs in plasma samples of 90 lung cancer patients and 85 healthy individuals. Receiver operating curves (ROC) with area under the curve (AUC) were used to assess accuracy of studied miRNAs for distinguishing LC patients from healthy individuals. The miRNA-448 and 4478 were significantly overexpressed in lung cancer patients compared to healthy people and these two molecules were qualified for further analysis. Combination ROC analysis of both biomarkers reached 90 % of sensitivity and 76.3 % of specificity (AUC = 0.896) for distinguishing operable (stage IA-IIB) non-small cell lung cancer (NSCLC) patients from healthy subjects. Our results suggest that the examination of miRNAs could be considered as potential lung cancer, non-invasive biomarkers.


Lung cancer Early detection Biomarkers miRNA-448 miRNA-4478 



This study is sponsored by the Polpharma Scientific Fundation.

Conflicts of interest



  1. 1.
    Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359:1267–380.CrossRefGoogle Scholar
  2. 2.
    Aberle DR, Adams AM, Berg CD, Black WC, Clappo JD, et al. National lung cancer screening trial research team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;39(365):395–409.Google Scholar
  3. 3.
    Bach PB, Mirkin JN, Oliver TK, Azzoli CG, Berry DA, Brawley OW, et al. Benefits and harms of CT screening for lung cancer: a systematic review. JAMA. 2012;307:2418–29.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Nikolaidis G, Raji OY, Markopoulou S, et al. DNA methylation biomarkers offer improved diagnostic efficiency in lung cancer. Cancer Res. 2012;72(22):5692–701.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Tang D, Shen Y, Wang M, et al. Identification of plasma microRNAs as novel noninvasive biomarkers for early detection of lung cancer. Eur J Cancer Prev. 2013;22(6):540–8.CrossRefPubMedGoogle Scholar
  6. 6.
    MacFarlane LA, Murphy PR. MicroRNA: biogenesis, function and role in cancer. Curr Genomics. 2010;11(7):537–61.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Lan H, Lu H, Wang X, Jin H. MicroRNAs as potential biomarkers in cancer: opportunities and challenges. BioMed Res Int. 2014: ID: 125094.Google Scholar
  8. 8.
    Zhang B, Pan X, Cobb GP, et al. microRNAs as oncogenes and tumor suppressors. Dev Biol. 2007;302(1):1–12.CrossRefPubMedGoogle Scholar
  9. 9.
    Mitchelli PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. PNAS. 2008;105(30):10513–8.CrossRefGoogle Scholar
  10. 10.
    Wozniak MB, Scelo G, Muller DC, Mukeria A, Zaridze D, Brennan P. Circulating microRNAs as non-invasive biomarkers for early detection of non-small cell lung cancer. PLoS One. 2015. doi: 10.1371/journal.pone.0125026.Google Scholar
  11. 11.
    Qi Z, Yang DY, Cao J. Increased micro-RNA 17, 21, and 192 gene expression improve early diagnosis in non-small cell lung cancer. Med Oncol. 2014;31:195.CrossRefPubMedGoogle Scholar
  12. 12.
    Wang RJ, Zheng YH, Wang P, Zhang JZ. Serum miR-125a-5p, miR-145 and miR-146a as diagnostic biomarkers in non-small cell lung cancer. Int J Clin Exp Pathol. 2015;8(1):765–71.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Powrózek T, Krawczyk P, Kowalski DM, Winiarczyk K, Olszyna-Serementa M, Milanowski J. Plasma circulating microRNA-944 and microRNA-3662 as potential histological type-specific early lung cancer biomarkers. Transl Res. 2015. doi: 10.1016/j.trsl.2015.05.009.PubMedGoogle Scholar
  14. 14.
    Chen X, Hu Z, Wang W, Ba Y, Ma L, Zhang C, et al. Identification of ten serum microRNAs from a genome-wide serum microRNA expression profile as novel noninvasive biomarkers for nonsmall cell lung cancer diagnosis. Int J Cancer. 2012;130:1620–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Boeri M, Verri C, Conte D, Roz L, Modena P, Facchinetti F, et al. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci U S A. 2011;108(9):3713–8.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Bianchi F, Nicassio F, Marzi M, et al. A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. EMBO Mol Med. 2011;3:495–503.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Lv Y, Lei Y, Hu Y, Ding W, Zhang C, Fang C. miR-448 negatively regulates ovarian cancer cell growth and metastasis by targeting CXCL12. Clin Transl Oncol. 2015. doi: 10.1007/s12094-015-1325-8.Google Scholar
  18. 18.
    McConnell BB, Ghaleb AM, Nandan MO, Yang VW. The diverse functions of Krüppel-like factors 4 and 5 in epithelial biology and pathobiology. Bioessays. 2007;29(6):549–57.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Deng L, Liu H. MicroRNA-506 suppresses growth and metastasis of oral squamous cell carcinoma via targeting GATA6. Int J Clin Exp Med. 2015;8(2):1862–70.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Deng J, Lei W, Xiang X, Zhang L, Yu F, Chen J, et al. MicroRNA-506 inhibits gastric cancer proliferation and invasion by directly targeting Yap1. Tumor Biol. 2015. doi: 10.1007/s13277-015-3364-8.Google Scholar
  21. 21.
    Tóth K, Galamb O, Spisak S, Wichmann B, Sipos F, Valcz G, et al. The influence of methylated septin 9 gene on RNA and protein level in colorectal cancer. Pathol Oncol Res. 2011;17(3):503–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Montagna C, Bajerano-Sagie M, Zechmeister JR. Mammalian septins in health and disease. Res Rep Biochem. 2015;5:59–72.CrossRefGoogle Scholar
  23. 23.
    Ghanbari R, Mosakhani N, Asadi J, Nouraee N, Mowla SJ, Poustchi H, et al. Decreased expression of fecal miR-4478 and miR-1295-3p in early-stage colorectal cancer. Cancer Biomark. 2015;15(2):195–201.CrossRefGoogle Scholar
  24. 24.
    Sozzi G, Boeri M, Verri C, et al. Clinical utility of plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study. J Clin Oncol. 2014;32(8):768–73.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Veronessi G, Bellomi M, Mulshine JL, et al. Lung cancer screening with low-dose computed tomography: a non-invasive diagnostic protocol baseline lung cancer nodules. Lung Cancer. 2008;61:340–9.CrossRefGoogle Scholar
  26. 26.
    Zhu W, He J, Chen D, Zhang B, Xu L, Ma H, et al. Expression of miR-29c, miR-93, and miR-429 as potential biomarkers for detection of early stage non-small lung cancer. PLoS ONE. 2014;9(2):e87780.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Foss KM, Sima C, Ugolini D, et al. miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer. J Thorac Oncol. 2011;6(3):482–8.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Tomasz Powrózek
    • 1
  • Paweł Krawczyk
    • 1
  • Dariusz M. Kowalski
    • 2
  • Barbara Kuźnar-Kamińska
    • 3
  • Kinga Winiarczyk
    • 2
  • Marta Olszyna-Serementa
    • 2
  • Halina Batura-Gabryel
    • 3
  • Janusz Milanowski
    • 1
  1. 1.Department of Pneumonology, Oncology, and AllergologyMedical University of LublinLublinPoland
  2. 2.Department of Lung and Chest Tumors, Oncology CentreInstitute M. Sklodowska - CurieWarsawPoland
  3. 3.Department of Pulmonology, Allergology, and Respiratory OncologyPoznan University of Medical SciencesPoznańPoland

Personalised recommendations